市場調查報告書

個體化癌症疫苗的全球市場:臨床試驗和未來預測

Global Personalized Cancer Vaccine Market, Clinical Trials & Future Outlook 2026

出版商 KuicK Research 商品編碼 914167
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
個體化癌症疫苗的全球市場:臨床試驗和未來預測 Global Personalized Cancer Vaccine Market, Clinical Trials & Future Outlook 2026
出版日期: 2019年10月01日內容資訊: 英文 170 Pages
簡介

本報告提供全球個體化癌症疫苗市場相關調查分析,以臨床革新為焦點,提供現狀,臨床性相關性,影響市場成長的趨勢與最近的進步,未來的預測等相關的系統性資訊。

第1章 個體化癌症疫苗:為未來的免疫治療藥帶來重大改革

  • 癌症疫苗策略性方法
  • 癌症疫苗 - 目前臨床試驗方案

第2章 個體化癌症疫苗的作用機制

  • 個體化癌症疫苗有關的實體及其貢獻
  • 個體化癌症疫苗的一般功能
  • 從遺傳基因多態性到藥物基因組學
  • 癌症醫藥基因學觀察體細胞變異

第3章 個體化疫苗上生物標記的重要性

  • 醫藥基因學的生物標記
  • 預後生物標記·預測生物標記

第4章 對個人化醫療的進行中的臨床試驗

  • 黑色素瘤
  • 個體化疫苗:胰臟癌
  • 轉移性大腸癌
  • 神經膠質母細胞瘤 (腦瘤)
  • HPV癌症

第5章 抵禦腫瘤增生的免疫查核點生物標記

  • CTLA4的新興生物標記
  • PD-1/PD-L1

第6章 個體化癌症疫苗:製造流程·成本分析

  • 製造前的成本分析
  • 個體化癌症疫苗的不同市場區隔成本分析
  • 每位病人的成本

第7章 個體化癌症疫苗市場的當前市場趨勢和進展

  • 改善未來個體化癌症疫苗成果的研究
  • 增資
  • 利用mRNA開發個體化癌症疫苗
  • 個體化癌症疫苗市場接受聯盟和風險投資並獲得穩定的資金
  • DNA測序技術的發展促進了個體化癌症疫苗市場

第8章 世界 - 個體化癌症疫苗市場區隔:各癌症類型

  • 黑色素瘤
  • 肺癌
  • 乳癌
  • 大腸癌
  • 白血病
  • 前列腺癌
  • 子宮頸癌
  • 神經膠質母細胞瘤 (腦瘤)

第9章 個體化癌症疫苗:新的手段和機會的崛起

  • 個體化癌症疫苗臨床開發流程的注意事項
  • 全球新興市場上個體化癌症疫苗的機會

第10章 個體化癌症疫苗市場的波特五力分析

第11章 促進個體化癌症疫苗市場的要素

第12章 個體化癌症疫苗市場的相關課題

第13章 全球個體化癌症疫苗市場未來發展預測

第14章 個人化醫療的現在市場各地區方案

  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東·非洲

第15章 全球個體化疫苗趨勢

第16章 競爭情形

  • Advaxis Inc.
  • Avax Technologies
  • BioNtech AG
  • Celldex
  • CureVac AG
  • Genetech
  • Genocea
  • Gristone Oncology
  • ISA Pharmaceuticals
  • Merck
  • Moderna Therapeutics
  • Neon Therapeutics
  • Personalis
目錄
  • Personalized Cancer Vaccine Mechanism of Action
  • Biomarkers Importance In Personalized Vaccines
  • Ongoing Clinical Trials on Personalized Cancer Vaccine
  • Developmental Cost Analysis of a Personalized Cancer Vaccine
  • Immune Checkpoint Biomarkers Preventing Tumor Growth
  • Advancements in the Personalized Cancer Vaccine
  • Current Market Trends & Advancements in the Personalized Cancer Vaccine Segment

The treatment of cancer through the aspect of using vaccine that has been personalized according to the requirement with an approach that the therapy will provide no harm in the future is innovative yet challenging. The concept of personalized vaccine is recognized as a paradigm shift for the way the cancer is treated and the way cancer is seen in the future. Although many other therapies are available in the present for the treatment of cancer but majority of the therapies come with their own drawbacks and undesirable outcomes.

Personalized vaccine allows us to take a giant step towards the treatment of cancer as in each person's cancer the case is different and the therapy is customized according to the individual cancer scenario. Personalized vaccines when compared with the already existing therapies, has accomplished a great success, with respect to the wide utilization of the treatment in different cancer types. The idea of fitting every cancer patient to the limited drugs has come to an end with the participation of this novel therapeutics into the active field of oncology.

The therapy approaches the development of a neoantigen vaccine that stimulates the immune system to attack the malignant cells in a unique way. Currently, the personalized cancer vaccine of immunotherapy segment is undergoing rapid advancements and improvements with the help of highly skilled researchers at the top universities and laboratories all around the world. Recent research published by some leading science journals reported excellent and emerging outcomes about the cancer vaccines. The current study about the segment is limited to lab animals, but once the testing is over, it will be tested in humans for the first time.

A number of clinical trials regarding the investigational therapy are currently mid-way of becoming the future of the cancer therapies. In the current scenario, USA and Europe are leading the race of having the major market players Increasing adoption to healthcare system and advancements in the genome sequencing techniques are the major contributors to the huge market share in the region.

The research and development of personalized vaccine is supported by both private as well as public sectors by rising their investments in the personalized cancer vaccine segment. The advantage of increasing fundings can provide a valuable option to the patients as well as the research sector. CureVac, Kite pharma, Alphabet, Modema & Merck are some of the major investors in the personalized cancer vaccine segment. The development made by the researchers play an important role in setting up newly available treatments as they will contribute significantly to the cancer treatment and driving the market size by many folds.

The idea behind the development of personalized vaccine is an exception from all the cancer treatments that we all are dependent on. As per report findings, personalized vaccine is successful in showing tremendous progress in the research area and in future it will be a promising approach for treating certain tumors and other inflammatory diseases related with cancer. In the upcoming years, increasing number of cancer patients is expected to increase the market size and revolutionize the entire market for cancer therapies available.

This report on the personalized cancer vaccine market provides a comprehensive insight into the current status of the segment with special emphasis on the clinical innovations governing the market. The report also highlights the clinical relevance of personalized cancer vaccine, trends and recent advances that will impact the growth of the market. Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2026.

Table of Contents

1. Personalized Cancer Vaccine: Revolutionizing the Immunotherapeutics of the Future

  • 1.1 The Approach Towards Cancer Vaccine Strategy
  • 1.2 Cancer Vaccines - Current Clinical Trials Scenario

2. Personalized Cancer Vaccine Mechanism of Action

  • 2.1 Entities Involved in Personalized Cancer Vaccine & Their Respective Contributions
    • 2.1.1 Tumor Neo - Antigens
    • 2.1.2 Human Leukocyte Antigen
  • 2.2 General Working of Personalized Cancer Vaccine
  • 2.3 Genetic Polymorphism Leading to Pharmacogenomics
  • 2.4 Cancer Pharmacogenomics Observing Somatic Mutations

3. Biomarkers Importance In Personalized Vaccines

  • 3.1 Pharmacogenomic Biomarkers
  • 3.2 Prognostic & Predictive Biomarkers

4. Ongoing Clinical Trials on Personalized Medicines

  • 4.1 NEO-PV-01 Showing Glimmers of Success against Melanoma
  • 4.2 Personalized Vaccine: An Evolving Biological Discovery for Pancreatic Cancer
  • 4.3 Precision Cancer Vaccine against Metastatic Colorectal Cancer
  • 4.4 First-in-Human Trial of Personalized Vaccine for Glioblastoma (Brain Tumor)
  • 4.5 TG4001 in Combination with Avelumab against HPV Cancers

5. Immune Checkpoint Biomarkers Preventing Tumor Growth

  • 5.1 Emerging Biomarkers for CTLA4
  • 5.2 PD-1/PD-L1

6. Personalized Cancer Vaccine: Manufacturing Process & Cost Analysis Study

  • 6.1 Pre - Manufacturing Cost Analysis
  • 6.2 Segmented Cost Analysis of Personalized Cancer Vaccine
    • 6.2.1 Capital Cost
    • 6.2.2 Cost of Raw Materials
    • 6.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
    • 6.2.4 Factory & Administrative Overheads
    • 6.2.5 Filling & Packaging
  • 6.3 Per Patient Cost

7. Current Market Trends & Advancements in the Personalized Cancer Vaccine Segment

  • 7.1 Researchers Improving the Outcome of Future Personalized Cancer Vaccine
  • 7.2 Increasing Investments
  • 7.3 Personalized Cancer Vaccine Development using mRNA
  • 7.4 Personalized Cancer Vaccine Market Receiving Collaborations & Ventures Ensure Stable Funding
  • 7.5 DNA Sequencing Technology Development Driving the Personalized Cancer Vaccine Market

8. Global - Personalized Cancer Vaccine Market Segmentation by Cancer Type

  • 8.1 Personalized Cancer Vaccine Breakthrough against Melanoma
  • 8.2 Lung Cancer Prevention using Personalized Vaccines
  • 8.3 Personalized Cancer Vaccines towards Eliminating Breast Cancer
  • 8.4 Colorectal Cancer Eradication by Personalized Cancer Vaccines
  • 8.5 Scope of Leukemia Treatment using Personalized Cancer Vaccines
  • 8.6 Prostate Cancer Eradication using Personalized Cancer vaccine: Provenge
  • 8.7 Personalized Cancer Vaccines Targeting Cervical Cancer
  • 8.8 Personalized Cancer Vaccines Application towards Glioblastoma (Brain Tumor)

9. Personalized Cancer Vaccine: Rising with New Avenues & Opportunities

  • 9.1 Insights into the Personalized Cancer Vaccine Clinical Pipeline
  • 9.2 Opportunities for Personalized Cancer Vaccine in the Emerging Market of the World

10. Porter's Five Force Analysis of the Personalized Cancer Vaccine Market

  • 10.1 Bargaining Power of Suppliers
  • 10.2 Bargaining Power of Buyer
  • 10.3 Threats of Substitute Products
  • 10.4 Threat of New Entrants to the already Existing Market
  • 10.5 Rivalry Among the Existing Competitors

11. Factors Driving the Market of Personalized Cancer Vaccine

  • 11.1 Increased Demand for Personalized Cancer Vaccine Production
  • 11.2 Increase Prevalence of Cancer Cases in the Population Worldwide
  • 11.3 Cancer Heterogenetic Environment
  • 11.4 High Level of Specificity
  • 11.5 Assistance from Government
  • 11.6 Advancements in Genome Sequencing Techniques Delivering better Personalized Cancer Vaccines
  • 11.7 Robust Clinical Pipeline Under Development

12. Challenges Associated with Personalized Cancer Vaccine Market

  • 12.1 Scientific & Technical Challenges in Developing a Personalized Cancer Vaccine
  • 12.2 Commercial Challenges Surrounding Personalized Cancer Vaccines

13. Global Personalized Cancer Vaccine Market Future Outlook

14. Personalized Medicine Current Market Region Scenario

  • 14.1 North America
  • 14.2 Latin America
  • 14.3 Europe
  • 14.4 Asia-Pacific
    • 14.4.1 Japan
    • 14.4.2 India
    • 14.4.3 South Korea
    • 14.4.4 Taiwan
  • 14.5 Middle East & Africa

15. Global Personalized Vaccine Trends

16. Competitive Landscape

  • 16.1 Advaxis Inc.
  • 16.2 Avax Technologies
  • 16.3 BioNtech AG
  • 16.4 Celldex
  • 16.5 CureVac AG
  • 16.6 Genetech
  • 16.7 Genocea
  • 16.8 Gristone Oncology
  • 16.9 ISA Pharmaceuticals
  • 16.10 Merck
  • 16.11 Moderna Therapeutics
  • 16.12 Neon Therapeutics
  • 16.13 Personalis

List of Figures

  • Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
  • Figure 1-2: Advantages of Targeting Neo - Antigens in Cancer Vaccine Production
  • Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
  • Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
  • Figure 2-3: The Sources of Pharmacological & Pharmacogenetic Variability's
  • Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
  • Figure 3-2: Roadmap of Development of Predictive Biomarkers
  • Figure 4-1: Ongoing Clinical Trials on Personalized Vaccines
  • Figure 5-1: High Throughput Immune Assessment for Biomarker Discovery
  • Figure 6-1: General Overview of Personalized Cancer Vaccine Production
  • Figure 6-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
  • Figure 6-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
  • Figure 6-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
  • Figure 6-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
  • Figure 6-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
  • Figure 6-7: Gardasil - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
  • Figure 6-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
  • Figure 6-9: Gardasil - Factory & Administrative Overheads (US$ Million), 2018
  • Figure 6-10: Cervarix - Factory & Administrative Overheads (US$ Million), 2018
  • Figure 6-11: Gardasil - Manufacturing Cost per single Dose (US$), 2018
  • Figure 6-12: Cervarix - Manufacturing Cost per single Dose (US$), 2018
  • Figure 6-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient), 2018
  • Figure 6-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
  • Figure 6-15: Gardasil & Gardasil 9 - Cost Analysis (US$), October' 2019
  • Figure 7-1: Trends & Advancement in the Personalized Cancer Vaccine Segment
  • Figure 7-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
  • Figure 8-1: Alteration in CDKN2A Mechanism
  • Figure 8-2: Global - Melanoma & Non - Melanoma Cancer Incidence (000'), 2018
  • Figure 8-3: Global - Melanoma Prevalence by Region (%), 2018
  • Figure 8-4: Global - Lung Cancer Incidence & Deaths (Million), 2018
  • Figure 8-5: Global - Lung Cancer Prevalence by Region (%), 2018
  • Figure 8-6: Global - Breast Cancer Incidence & Deaths (Million), 2018
  • Figure 8-7: Global - Breast Prevalence by Region (%), 2018
  • Figure 8-8: Global - Colorectal Cancer Incidence & Deaths (Million), 2018
  • Figure 8-9: Global - Colorectal Cancer Market Size (%), 2018
  • Figure 8-10: Global - Leukemia Incidence (000'), 2018
  • Figure 8-11: Global - Leukemia Market Size (%), 2018
  • Figure 8-12: Global - Prostate Cancer Incidence (000'), 2018
  • Figure 8-13: Global - Prostate Cancer Prevalence by Region (%), 2018
  • Figure 8-14: Provenge - Cost Analysis (US$/Month)
  • Figure 8-15: Global - Cervical Cancer Incidence (000'), 2018
  • Figure 8-16: Global - Cervical Cancer prevalence by Region (%), 2018
  • Figure 9-1: Global - Oncology Market Size by Region (%), 2017
  • Figure 10-1: Porter's Five Force Analysis - Overview
  • Figure 11-1: Driving Factors of the Personalized Cancer Vaccine Market
  • Figure 11-2: Global - Most Common Types of Cancer by Prevalence, 2018
  • Figure 11-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
  • Figure 11-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
  • Figure 12-1: Scientific Limitations in Personalized Cancer Vaccine Development
  • Figure 13-1: Global - Gardasil/ Gardasil 9 Sales (US$ Billion), 2018 -2026
  • Figure 13-2: Gardasil/ Gardasil 9 Sales - US v/s Rest of World (US$ Billion), 2018
  • Figure 13-3: Gardasil/ Gardasil 9 - Global Patent Insight
  • Figure 13-4: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2019 - 2026
  • Figure 14-1: US - Total Cancer Deaths, 2016 - 2018
  • Figure 14-2: Europe - Total Cancer Deaths, 2016 - 2018
  • Figure 14-3: Asia-Pacific - Total Cancer Deaths, 2018
  • Figure 14-4: Japan - Total Cancer Deaths, 2016 & 2018
  • Figure 14-5: India - Total Cancer Deaths, 2014 & 2018
  • Figure 14-6: South Korea - Total Cancer Deaths, 2014 - 2016
  • Figure 14-7: Taiwan - Total Cancer Deaths, 2017 - 2018

List of Tables

  • Table 8-1:Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
  • Table 8-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia
Back to Top